Jceler M Jceler M2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby enhancing insulin secretion and improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and increases peripheral insulin sensitivity, facilitating better glucose uptake by muscle tissues. The combination of these two agents offers a complementary mechanism of action, effectively lowering blood glucose levels in patients inadequately controlled by diet and exercise alone. Jceler M Jceler M2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as the risk of hypoglycemia due to glimepiride. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. This combination therapy should be used under medical supervision to optimize glycemic control and minimize potential risks.